R cell migration and proliferation. Neoplasia 2006, 8:57886.Astrocytes have been grown in principal culture as described previously [62]. Briefly, the cerebral hemispheres of newborn SJL and G1H+/- mice have been removed, the meninges were carefully removed off, and the cerebral tissues had been dissociated with trypsin. The dissociated cells were seeded at 1.4 104 viable cells/cm2 in a plastic culture flask and grown for 2 weeks in Dulbecco’s modified Eagle’s medium with 20 F-12 and 10 fetal bovine serum at 37 inside a five CO2 incubator. Just before experiments, immunocytochemistry confirmed that more than 95 in the cells had been stained positively for the astrocytic marker GFAP. For proliferation assay, cells were plated on 96-well plates (four 103 cells/well) andKawaguchi-Niida et al. Acta Neuropathologica Communications 2013, 1:21 http://www.actaneurocomms.org/content/1/1/Page 11 of10. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, Melhem MF, Yao Z, Zhang J: Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine issue for prostate cancer growth and invasion. Prostate 2006, 66:1311318. 11. El Khoury J, Luster AD: Mechanisms of microglia accumulation in Alzheimer’s disease: therapeutic implications. Trends Pharmacol Sci 2008, 29:62632. 12. Huang DR, Wang J, Kivisakk P, Rollins BJ, Ransohoff RM: Absence of monocyte chemoattractant protein 1 in mice results in decreased nearby macrophage recruitment and antigen-specific T helper cell form 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med 2001, 193:71326. 13. Hughes PM, Allegrini PR, Rudin M, Perry VH, Mir AK, Wiessner C: Monocyte chemoattractant protein-1 deficiency is protective within a murine stroke model. J Cereb Blood Flow Metab 2002, 22:30817. 14. Baron P, Bussini S, Cardin V, Corbo M, Conti G, Galimberti D, Scarpini E, Bresolin N, Wharton S, Shaw PJ, Silani V: Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. Muscle Nerve 2005, 32:54144. 15. Gupta PK, Prabhakar S, Sharma S, Anand A: A predictive model for amyotrophic lateral sclerosis (ALS) diagnosis. J Neurol Sci 2012, 312:682. 16. Henkel JS, Engelhardt JI, Sikl L, Simpson EP, Kim SH, Pan T, Goodman JC, Siddique T, Beers DR, Appel SH: Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue.SNPB Ann Neurol 2004, 55:22135. 17. Simpson EP, Henry YK, Henkel JS, Smith RG, Appel SH: Increased lipid peroxidation in sera of ALS sufferers: a potential biomarker of illness burden. Neurology 2004, 62:1758765. 18. Wilms H, Sievers J, Dengler R, Bufler J, Deuschl G, Lucius R: Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further proof for microglial activation in neurodegeneration.Vunakizumab J Neuroimmunol 2003, 144:13942.PMID:23991096 19. Beers DR, Zhao W, Liao B, Kano O, Wang J, Huang A, Appel SH, Henkel JS: Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav Immun 2011, 25:1025035. 20. Henkel JS, Beers DR, Sikl L, Appel SH: The chemokine MCP-1 and the dendritic and myeloid cells it attracts are enhanced within the mSOD1 mouse model of ALS. Mol Cell Neurosci 2006, 31:42737. 21. Mantovani S, Garbelli S, Pasini A, Alimonti D, Perotti C, Melazzini M, et al: Immune technique alterations in sporadic amyotrophic lateral sclerosis patients recommend an ongoing neuroinflammatory process. J Neuroimmunol 2009, 210:739. 22. Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J.
